Help might be on the way just as new coronavirus infections start to appear in the United States.
The Pfizer-BioNTech COVID-19 vaccination for children ages 5 to 11 was unanimously recommended by a federal advisory group on Tuesday, providing comfort to millions of parents because up to 28 million youngsters would be eligible for the doses.
Vaccines For Children May Come To The Rescue
The immunizations were officially approved by Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, later Tuesday, and maybe accessible at pharmacies and physicians’ offices as early as Wednesday.
The timing couldn’t be better, given that the number of new viral cases in the United States has increased by 5.4 percent in the previous week, indicating that the delta variant-driven wave isn’t yet over.
According to a USA TODAY review of Johns Hopkins University data, there were 523,194 new cases countrywide in the week ending Monday, up from 495,194 the previous week. At this rate, 52 new infections are discovered per minute.
According to the study, instances are on the rise in 23 states, up from eight just a week ago.
Before the delta effect kicked in around July 1, weekly cases had dropped to less than 80,000, or less than one-sixth of what they are now. At their plight
Deaths have been decreasing, which is a lagging sign. The United States recorded 9,119 COVID-19 fatalities in the week ending Monday, a decrease of nearly 100 per day from the prior average of 1,400 per day.
The Pfizer-BioNTech COVID-19 vaccination for children ages 5 to 11 received unanimous approval from a CDC advisory group on Tuesday, and it might be accessible this week in some places as early as Wednesday.
Dr. Rochelle Walensky, the Director of the Centers for Disease Control and Prevention, signed off on the immunizations on Tuesday night, clearing the final obstacle. “There are children in the second grade who have never experienced a regular school year,” she stated before the advisory group made its decision. The immunization of children has been proven to be effective.
The vaccine, which will be free, will be administered in two doses at least three weeks apart, at one-third the dose provided to adolescents and adults. In this age bracket, only the Pfizer-BioNTech vaccine would be available. Adolescents and children are still being tested for the Moderna and Johnson & Johnson vaccinations.
Pfizer-BioNTech found no major adverse effects associated with the doses in multiple minor studies, however, some are anticipated to emerge when millions of youngsters take the vaccine.
Headaches, weariness, muscular soreness, pain at the injection site, and vomiting, nausea, or diarrhea are common side effects that go away in a day or two. The vaccination was shown to be effective in a study of roughly 2,500 youngsters.
While mass immunization sites and chain pharmacies were first used to spread the COVID-19 vaccine across the country, physicians are now anticipated to play a bigger role.ṣ